Ignite Creation Date:
2024-05-06 @ 12:20 AM
Last Modification Date:
2024-10-26 @ 10:48 AM
Study NCT ID:
NCT01553500
Status:
COMPLETED
Last Update Posted:
2014-04-02
First Post:
2011-10-03
Brief Title:
Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease
Sponsor:
Bambino Gesù Hospital and Research Institute
Organization:
Bambino Gesù Hospital and Research Institute
Study Overview
Official Title:
Study of the Efficacy and Tolerability of Glucomannan on Children Affected by NAFLD
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GC-NASH
Brief Summary:
Non-alcoholic fatty liver disease NAFLD has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children The pathogenesis of NAFLD is generally considered the result of a series of liver injuries commonly referred as multi-hit hypothesis Insulin resistance and increased serum levels of free fatty acids FFAs are considered the main primary hits that lead to the excessive lipid accumulation in hepatocytes resulting in steatosis
Has been reported that a diet rich in high-viscosity fiber improves glycemic control and lipid profile suggesting a therapeutic potential role in the treatment of NAFLD
Aim of this study is to evaluate the efficacy and tolerability of glucomannan in children affected by non alcoholic fatty liver disease
Has been reported that a diet rich in high-viscosity fiber improves glycemic control and lipid profile suggesting a therapeutic potential role in the treatment of NAFLD
Aim of this study is to evaluate the efficacy and tolerability of glucomannan in children affected by non alcoholic fatty liver disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None